Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigen, Bionomics Expand Target-Discovery Collaboration

NEW YORK, Jan. 30 - Hybrigen and Bionomics have expanded their drug target-discovery relationship to include a new angiogenesis target discovered by Bionomics, the companies said on Wednesday.


They also announced plans jointly to launch a new enterprise to commercialize discoveries made in the collaboration.


The two companies inked a target discovery partnership last September to study two genes linked to breast cancer. Bionomics had identified and patented the genetic data, and Hybrigen brought its proteomic expertise to discover relevant drug targets. The two companies share rights to any drug targets developed in that collaboration.


The relationship will now include Bionomics' angiogenesis genes to which it has rights. Again, both companies will co-own the drug targets.


Bionomics, based in Adelaide, Australia, focuses on discovering and characterizing disease-related genes, especially in breast cancer, epilepsy, and angiogenesis.


Hybrigen is headquartered in Dallas, Tex. It has developed a proteomic platform to assist in drug target-discovery and characterization.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.